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Abstract
Background: Metastatic involvement of the ovary from malignant melanoma is uncommon and
presents a diagnostic challenge. Most cases are associated with disseminated disease and carry a
dismal prognosis. Delayed ovarian recurrences from melanoma may mimic primary ovarian cancer
and lead to aggressive cytoreductive procedures.
Case presentation: A case of malignant melanoma in a premenopausal patient is presented with
late abdominal and ovarian metastatic spread, where ascitic fluid cytology led to an accurate
preoperative diagnosis and the avoidance of unnecessary surgical procedures.
Conclusion: Secondary ovarian involvement is associated with a poor prognosis and efforts
should be made for adequate palliation. Pathologic diagnosis with non-invasive procedures is crucial
in order to avoid unnecessary surgery. Surgical interventions may be undertaken only in selected
cases of limited metastatic disease, where complete resection is expected
Background
The ovary is a frequent site of secondary spread from
extra-ovarian malignancies. Approximately 6–7% of the
patients presenting with suspected ovarian neoplasm will
prove to suffer from metastatic disease to the ovary [1].
Besides gynecologic cancers, which tend to involve the
ovaries by direct invasion, gastrointestinal adenocarcino-
mas, followed by breast cancer are the most common
nongynecologic malignancies, which metastasize to the
ovaries [1,2]. Ovarian involvement by metastatic malig-
nant melanoma is relatively uncommon and it is rare for
melanoma to present clinically as an ovarian mass [3].
Case presentation
A 43-year old female patient was referred to our depart-
ment with the clinical diagnosis of ovarian malignancy.
Abdominal CT scan revealed a left adnexal mass, moder-
ate perihepatic and perisplenic ascitic fluid collection, ret-
roperitoneal and pelvic lymph node enlargement and
omental cake peritoneal seedings; thorax CT identified a
paravertebral pleural cystic lesion with thick wall and
serous liquid content (Fig. 1). Laboratory investigations
showed a mildly elevated serum lactate dehydrogenase at
546 IU/L and CA 125 at 1420 IU/L. The patient's previous
history was remarkable for a malignant melanoma of the
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left antecubital region removed surgically 9 years ago. His-
topathology report at that time revealed a Breslow 2.36
mm, Clark's level IV, superficial spreading melanoma
with a nodular phase growth pattern, with signs of regres-
sion and without ulceration. Elective left axillary lymph
node dissection and intraoperative isolated limb per-
fusion of the left upper extremity with cisplatin, melpha-
lan and dacarbazine was performed according to an
investigational protocol at the time of initial presentation
of the patient. Histopathologic examination showed no
evidence of metastatic disease in the excised lymph nodes.
After 2 years of well being the patient was lost from fol-
low-up. In order to establish a definite diagnosis of the
present clinical scenario, ultra-sound guided aspiration of
the ascitic fluid and cytopathological examination was
performed. Cytological morphology showed a cellular
Thoracic and abdominal CT scans of the patient at initial presentation Figure 1
Thoracic and abdominal CT scans of the patient at initial presentation.
Melanoma cells showing strong positivity for Vimentin (left) and HMB-45 (right) (liquid based cytology – ThinPrep × 400) Figure 2
Melanoma cells showing strong positivity for Vimentin (left) and HMB-45 (right) (liquid based cytology – Thin-
Prep × 400).World Journal of Surgical Oncology 2008, 6:124 http://www.wjso.com/content/6/1/124
Page 3 of 4
(page number not for citation purposes)
smear with a single cell population of large pleomorphic
round undifferentiated pigmented malignant cells with
moderate to abundant cytoplasm. The hyperchromatic
nuclei showed great variation in size and contained large
nucleoli. There was pigment both within the cytoplasm
and in the background. Binucleate and multinucleated
cells were also frequent. Immunocytochemistry studies
revealed positivity for HMB-45, vimentin and S-100 (Fig.
2). The findings were identical to the initial specimen of
the same patient and diagnostic of metastatic melanoma.
Systemic cisplatin-based cytotoxic chemotherapy was ini-
tiated. After a short period of disease stabilization the
patient developed brain metastases and died 8 months
after the diagnosis of disease relapse.
Discussion
Primary epithelial ovarian cancer (EOC) is the leading
cause of death from gynecologic cancer [4]. The ovary is
also a frequent site of secondary spread from extra-ovarian
malignant neoplasms. Ovarian involvement most com-
monly occurs via contiguous spread from neighboring
organs or via the peritoneal route. Most common primary
tumors include gynecologic and gastrointestinal cancers
[1,5]. Other malignancies, such as breast cancer and
malignant melanoma involve the ovaries secondarily
through the hematogenous route [2,3]. Ovarian metasta-
sis is generally associated with a poor prognosis [1,2].
Melanoma involving the ovary is uncommon and it rarely
presents clinically as an ovarian mass [6]. Ovarian
involvement occurs in up to 20% of patients with
melanoma in autopsy series, however premortem diagno-
sis is uncommon, mostly due to the fact that it is com-
monly associated with disseminated disease and is
therefore clinically irrelevant [7]. Our patient had an
intermediate risk, stage IIA (T3a) melanoma, thus a 36%
risk of death at 10 years [8]. Adverse prognostic features
included the presence of histologic regression, whereas
age, sex and anatomic location of her primary lesion were
favourable. However delayed disease recurrences have
been observed as late as 27 years after initial diagnosis
even in early stage melanomas [9]. Although 95% of dis-
ease recurrences in Stage III melanoma occur within 5
years, node-negative melanomas, thin or non-ulcerated
lesions, younger age, as well as adjuvant treatment tend to
correlate with delayed recurrences [10]. The time interval
between the diagnosis of the primary melanoma and
ovarian metastasis has ranged from months up to 18 years
[3].
Most metastatic tumors involve both ovaries. On the con-
trary, ovarian metastases from melanoma are mostly uni-
lateral [3], as in our patient. Women of reproductive age
are more prone to metastatic ovarian involvement, which
may be attributed to the higher blood flow to the premen-
opausal ovary [2]. The extremities are the most frequent
primary localization of melanoma, secondarily involving
the ovaries [3], as in our patient.
Cases of ovarian metastasis from melanoma published so
far have been almost invariably diagnosed following sur-
gical treatment [3,6,7,11]. Survival was poor despite
aggressive surgical debulking with or without adjuvant
therapy. A more favorable subset of patients with meta-
static ovarian involvement included gynecologic [5] or
colonic primaries [12], isolated ovarian metastasis [2],
absence of extrapelvic or extra-abdominal disease [12]
and complete surgical resection of metastatic disease
[2,12]. In contrast to primary EOC, there is no proven
value for cytoreductive surgery in women with cancer met-
astatic to the ovaries [2]. Surgery is generally indicated in
terms of diagnostic laparotomy or palliative procedures in
painful or obstructing metastatic lesions.
In our patient, the remote history of melanoma was
ignored, considered irrelevant to the present clinical pres-
entation. A diagnosis of advanced ovarian malignancy
was suspected and a neoadjuvant taxane-platinum chem-
otherapy was proposed. In order to obtain pathologic
diagnosis to guide further treatment, ascitic fluid cytology
was performed. Neoplastic cells were identified with fea-
tures consistent with the diagnosis of metastatic
melanoma. The findings were identical to the initial spec-
imen of the same patient and diagnostic of metastatic
melanoma. Immunocytochemistry was positive for HMB-
45, vimentin and S-100. S-100 and HMB-45 are the two
most sensitive markers, being positive in 95% and 85% of
melanoma cases respectively [3].
The fact that the cytopathologist was made aware of the
previous history of melanoma was crucial; otherwise the
clinical picture simulating ovarian cancer may have lead
to a different therapeutic strategy. Even more challenging
are the cases without an obvious history of melanoma. A
regressed primary lesion may underlie such cases or the
rare primary ovarian melanoma arising within a teratoma
[3]. Another clue to an extra-ovarian origin in such clinical
cases is the presence of metastases to sites not usually seen
with primary ovarian cancer, such as the brain or skin [7].
In only one case so far, described by Moselhi et al [11],
diagnosis was established preoperatively via ascitic fluid
cytology. However, it was a case with evident pulmonary
nodules and lytic bone lesions, which were highly
unlikely to be due to EOC.
The elevated serum LDH was a hint in our patient and
after establishing diagnosis it was helpful in assessing dis-
ease burden. Serum lactate dehydrogenase seems to be a
simple yet quite powerful predictor of survival in patients
with metastatic melanoma [13]. Tumor marker elevationWorld Journal of Surgical Oncology 2008, 6:124 http://www.wjso.com/content/6/1/124
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was misleading and imaging studies were only indicative
of a malignant process, but not conclusive. Serum S-100
might have been helpful if available, although it is of lim-
ited value in the metastatic setting [14].
Initial staging should evaluate thoroughly disease extent,
in order to establish the diagnosis of potentially respecta-
ble metastatic disease. Surgical treatment for abdominal
metastases of melanoma in one report significantly pro-
longed survival; however complete resection was only
possible in one-third of the patients [15]. Unilateral salp-
ingo-oophorectomy has been proposed as an appropriate
treatment for metastatic melanoma involving the ovary, if
there is no evidence of contralateral ovarian involvement
or extraovarian spread [2,7]. In such cases of apparently
resectable metastatic disease, preoperative screening for
metastatic disease in other sites is crucial, either with con-
ventional imaging or with PET scanning [16]. No postop-
erative adjuvant therapy is of proven benefit for
improving survival [7,17]. In our patient the evidence of
diffuse abdominal metastatic involvement rendered the
disease irresectable and the therapeutic target was pallia-
tion.
Conclusion
The present case illustrates the unpredictable and diverse
natural history of malignant melanoma. It also highlights
the importance of a previous history of melanoma in a
patient presenting with signs of a second primary malig-
nancy even after a long remission period. Certain param-
eters should be considered to establish a definite
diagnosis and avoid unnecessary surgical intervention.
Disease recurrence should always be taken in account,
even after long periods of remission. Secondary ovarian
involvement is associated with a poor prognosis and
efforts should be made for adequate palliation. Patho-
logic diagnosis with non-invasive procedures is crucial in
order to avoid unnecessary surgery. Surgical interventions
may be undertaken only in selected cases of limited met-
astatic disease, where complete resection is expected.
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